BR0010573A - Métodos de tratamento ou prevenção, em um paciente, de ansiedade, de um estado convulsivo, de espasticidade ou espasmos musculares agudos, de um distútbios afetivo de um comportamento agressivo, de vìcio de drogas ou álcool, de nìveis de hormÈnio no plasma anormais, de distúrbio do sono, de uma doença ou condição ou sintoma da mesma, em um paciente afetado pela modulação de um ou mais dos receptores de benzodiazepina centrais ou periféricos, composição farmacêutica, forma de dosagem individual de n-desmetilzopiclona, métodos para preparar n-desmetilzopiclona, e racêmica, para preparar (+), e (-) n-desmetil zopiclona, e, para aumentar a pureza óptica de zopiclona ou desmetilzopiclona - Google Patents
Métodos de tratamento ou prevenção, em um paciente, de ansiedade, de um estado convulsivo, de espasticidade ou espasmos musculares agudos, de um distútbios afetivo de um comportamento agressivo, de vìcio de drogas ou álcool, de nìveis de hormÈnio no plasma anormais, de distúrbio do sono, de uma doença ou condição ou sintoma da mesma, em um paciente afetado pela modulação de um ou mais dos receptores de benzodiazepina centrais ou periféricos, composição farmacêutica, forma de dosagem individual de n-desmetilzopiclona, métodos para preparar n-desmetilzopiclona, e racêmica, para preparar (+), e (-) n-desmetil zopiclona, e, para aumentar a pureza óptica de zopiclona ou desmetilzopiclonaInfo
- Publication number
- BR0010573A BR0010573A BR0010573-2A BR0010573A BR0010573A BR 0010573 A BR0010573 A BR 0010573A BR 0010573 A BR0010573 A BR 0010573A BR 0010573 A BR0010573 A BR 0010573A
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- demethylzopiclone
- zopiclone
- patient
- desmethylzopiclone
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 230000002093 peripheral effect Effects 0.000 title abstract 6
- CGSFZSTXVVJLIX-HNNXBMFYSA-N N-Desmethylzopiclone Chemical compound N1=CC(Cl)=CC=C1N1C(=O)C2=NC=CN=C2[C@@H]1OC(=O)N1CCNCC1 CGSFZSTXVVJLIX-HNNXBMFYSA-N 0.000 title abstract 4
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 title abstract 2
- 208000019901 Anxiety disease Diseases 0.000 title abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title abstract 2
- 208000008238 Muscle Spasticity Diseases 0.000 title abstract 2
- 208000005392 Spasm Diseases 0.000 title abstract 2
- 230000002159 abnormal effect Effects 0.000 title abstract 2
- 230000001154 acute effect Effects 0.000 title abstract 2
- 230000036506 anxiety Effects 0.000 title abstract 2
- 230000002920 convulsive effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 229940088597 hormone Drugs 0.000 title abstract 2
- 239000005556 hormone Substances 0.000 title abstract 2
- 230000003287 optical effect Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 208000019116 sleep disease Diseases 0.000 title abstract 2
- 208000018198 spasticity Diseases 0.000 title abstract 2
- 208000024891 symptom Diseases 0.000 title abstract 2
- 229960000820 zopiclone Drugs 0.000 title abstract 2
- 208000017194 Affective disease Diseases 0.000 title 1
- 206010001488 Aggression Diseases 0.000 title 1
- 206010012335 Dependence Diseases 0.000 title 1
- 102000004300 GABA-A Receptors Human genes 0.000 title 1
- 108090000839 GABA-A Receptors Proteins 0.000 title 1
- 208000019022 Mood disease Diseases 0.000 title 1
- 208000007101 Muscle Cramp Diseases 0.000 title 1
- 230000016571 aggressive behavior Effects 0.000 title 1
- 208000012761 aggressive behavior Diseases 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000020685 sleep-wake disease Diseases 0.000 title 1
- SWWQQSDRUYSMAR-UHFFFAOYSA-N 1-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol;hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1CC1C2=CC(O)=C(O)C=C2CCN1 SWWQQSDRUYSMAR-UHFFFAOYSA-N 0.000 abstract 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000003542 behavioural effect Effects 0.000 abstract 1
- 229940049706 benzodiazepine Drugs 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000022925 sleep disturbance Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
"MéTODOS DE TRATAMENTO OU PREVENçãO, EM UM PACIENTE, DE ANSIEDADE, DE UM ESTADO CONVULSIVO, DE ESPASTICIDADE OU ESPASMOS MUSCULARES AGUDOS, DE UM DISTúRBIO AFETIVO, DE UM DISTúRBIO COMPORTAMENTAL, DE UM DISTURBIO ESQUIZOFRêNICO, DE UM COMPORTAMENTO AGRESSIVO, DE VìCIO DE DROGAS OU áLCOOL, DE NìVEIS DE HORMÈNIO NO PLASMA ANORMAIS, DE DISTúRBIO DO SONO, DE UMA DOENçA OU CONDIçãO OU SINTOMA DA MESMA, EM UM PACIENTE AFETADO PELA MODULAçãO DE UM OU MAIS DOS RECEPTORES DE BENZODIAZEPINA CENTRAIS OU PERIFéRICOS, COMPOSIçãO FARMACêUTICA, FORMA DE DOSAGEM INDIVIDUAL DE N-DESMETILZOPICLONA, MéTODOS PARA PREPARAR NDESMETILZOPICLONA, E RACêMICA, PARA PREPARAR ( + ), E ( - ) N-DESMETILZOPICLONA, E, PARA AUMENTAR A PUREZA óPTICA DE ZOPICLONA OU DESMETILZOPICLONA". A invenção é dirigida a composições compreendendo, e métodos de usar, N-desmetilzopiclona racêmica, ( + ) N-desmetilzopiclona opticamente pura, e ( - ) N-desmetilzopiclona opticamente pura, no tratamento e prevenção de doenças e condições em mamíferos. A invenção é ainda dirigida a novos métodos de preparação de N-desmetilzopiclona, ( + ) Ndesmetilzopiclona opticamente pura, e ( - ) N-desmetilzopiclona opticamente pura.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13423999P | 1999-05-14 | 1999-05-14 | |
| US13503799P | 1999-05-20 | 1999-05-20 | |
| US09/548,607 US6339086B1 (en) | 1999-05-14 | 2000-04-13 | Methods of making and using N-desmethylzopiclone |
| PCT/US2000/012820 WO2000069442A1 (en) | 1999-05-14 | 2000-05-11 | Methods of making and using n-desmethylzopiclone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0010573A true BR0010573A (pt) | 2002-06-04 |
Family
ID=27384542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0010573-2A BR0010573A (pt) | 1999-05-14 | 2000-05-11 | Métodos de tratamento ou prevenção, em um paciente, de ansiedade, de um estado convulsivo, de espasticidade ou espasmos musculares agudos, de um distútbios afetivo de um comportamento agressivo, de vìcio de drogas ou álcool, de nìveis de hormÈnio no plasma anormais, de distúrbio do sono, de uma doença ou condição ou sintoma da mesma, em um paciente afetado pela modulação de um ou mais dos receptores de benzodiazepina centrais ou periféricos, composição farmacêutica, forma de dosagem individual de n-desmetilzopiclona, métodos para preparar n-desmetilzopiclona, e racêmica, para preparar (+), e (-) n-desmetil zopiclona, e, para aumentar a pureza óptica de zopiclona ou desmetilzopiclona |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US6339086B1 (pt) |
| EP (1) | EP1183030A4 (pt) |
| JP (1) | JP2002544232A (pt) |
| KR (1) | KR20020008405A (pt) |
| AU (1) | AU776000B2 (pt) |
| BR (1) | BR0010573A (pt) |
| CA (1) | CA2373797C (pt) |
| MX (1) | MXPA01011534A (pt) |
| NO (2) | NO321674B1 (pt) |
| NZ (1) | NZ515626A (pt) |
| TR (1) | TR200200260T2 (pt) |
| WO (1) | WO2000069442A1 (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339086B1 (en) * | 1999-05-14 | 2002-01-15 | Swpracor, Inc. | Methods of making and using N-desmethylzopiclone |
| AU2003285012A1 (en) * | 2002-10-24 | 2004-05-13 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
| US20040248798A1 (en) | 2003-02-14 | 2004-12-09 | Peter Sutovsky | Contraceptive methods and compositions related to proteasomal interference |
| WO2005060968A1 (en) * | 2003-12-11 | 2005-07-07 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| US20050215521A1 (en) * | 2003-12-22 | 2005-09-29 | Karim Lalji | Modafinil combination therapy for improving sleep quality |
| EP1696959A2 (en) * | 2003-12-24 | 2006-09-06 | Sepracor, Inc. | Melatonin combination therapy for improving sleep quality |
| CA2556870C (en) * | 2004-02-18 | 2014-01-28 | Timothy J. Barberich | Dopamine-agonist combination therapy for improving sleep quality |
| EP1720568A2 (en) | 2004-02-19 | 2006-11-15 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral rna oligonucleotides |
| US7776858B2 (en) * | 2004-04-05 | 2010-08-17 | Sepracor Inc. | Methods of treatment of chronic pain using eszopiclone |
| WO2006136866A1 (en) * | 2005-06-21 | 2006-12-28 | Generics [Uk] Limited | Process for enantiomeric separation of zopiclone |
| US7476737B2 (en) * | 2005-09-05 | 2009-01-13 | Dr. Reddy's Laboratories Limited | Eszopiclone process |
| US20080027223A1 (en) * | 2006-03-23 | 2008-01-31 | Teva Pharmaceutical Industries Ltd. | Polymorphs of eszopiclone malate |
| US20070270590A1 (en) * | 2006-04-20 | 2007-11-22 | Marioara Mendelovici | Methods for preparing eszopiclone crystalline form a, substantially pure eszopiclone and optically enriched eszopiclone |
| US20080015197A1 (en) * | 2006-06-26 | 2008-01-17 | Alex Mainfeld | Process for the preparatrion of zopiclone |
| TW200846340A (en) * | 2007-01-31 | 2008-12-01 | Teva Pharma | Methods for preparing eszopiclone |
| US20090018336A1 (en) * | 2007-06-25 | 2009-01-15 | Nina Finkelstein | Racemization process of R-zopiclone |
| WO2009063486A2 (en) * | 2007-08-06 | 2009-05-22 | Usv Limited | Process for preparation of dextrorotatory isomer of 6-(5-chloro-pyrid-2-yi)-5-[(4-methyl -1-piperazinyl) carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo [3,4-b] pyrazine (eszopiclone) |
| US20110053945A1 (en) * | 2007-12-19 | 2011-03-03 | Sepracor Inc. | Salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihy-dro-5h-pyrrolo[3,4-b]pyrazine |
| CN101607961B (zh) * | 2008-06-18 | 2011-08-10 | 天津天士力集团有限公司 | 一种右佐匹克隆结晶及其组合物 |
| CA2742725A1 (en) | 2008-11-07 | 2010-05-14 | Cipla Limited | Process for resolving zopiclone |
| EP2345654A1 (en) | 2010-01-05 | 2011-07-20 | LEK Pharmaceuticals d.d. | Eszopiclone particles and a process for their preparation |
| EP2345655A1 (en) | 2010-01-05 | 2011-07-20 | LEK Pharmaceuticals d.d. | A process for racemisation of 6-(5-chloropyridin-2-yl)-7-(4-methyl-1-piperazinyl)carbonyloxy-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine |
| CN103980278B (zh) * | 2012-12-26 | 2017-05-10 | 上海中西制药有限公司 | 右佐匹克隆微晶及其制备方法 |
| JP2020007252A (ja) * | 2018-07-05 | 2020-01-16 | アクティブファーマ株式会社 | エスゾピクロンジベンゾイル−ｄ−酒石酸塩の製造方法、エスゾピクロンの製造方法、及びエスゾピクロンジベンゾイル−ｄ−酒石酸塩の結晶 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| OA04285A (fr) | 1972-01-07 | 1979-12-31 | Rhone Poulenc Sa | Nouveaux dérivés de la pyrrolo (3,4-b) pyrazine et leur préparation. |
| AR208414A1 (es) | 1974-11-07 | 1976-12-27 | Rhone Poulenc Ind | Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2) |
| FR2671800B1 (fr) * | 1991-01-17 | 1993-03-12 | Rhone Poulenc Rorer Sa | Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent. |
| AU3245593A (en) | 1991-12-02 | 1993-06-28 | Sepracor, Inc. | Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone |
| US5786357A (en) * | 1991-12-02 | 1998-07-28 | Sepracor Inc. | Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone |
| WO1993010788A1 (en) | 1991-12-02 | 1993-06-10 | Sepracor, Inc. | Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (-) zopiclone |
| US6339089B2 (en) * | 1997-08-13 | 2002-01-15 | Fujirebio Inc. | Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same |
| US6339086B1 (en) * | 1999-05-14 | 2002-01-15 | Swpracor, Inc. | Methods of making and using N-desmethylzopiclone |
-
2000
- 2000-04-13 US US09/548,607 patent/US6339086B1/en not_active Expired - Lifetime
- 2000-05-11 BR BR0010573-2A patent/BR0010573A/pt not_active IP Right Cessation
- 2000-05-11 JP JP2000617901A patent/JP2002544232A/ja active Pending
- 2000-05-11 KR KR1020017014541A patent/KR20020008405A/ko not_active Abandoned
- 2000-05-11 MX MXPA01011534A patent/MXPA01011534A/es active IP Right Grant
- 2000-05-11 CA CA2373797A patent/CA2373797C/en not_active Expired - Lifetime
- 2000-05-11 WO PCT/US2000/012820 patent/WO2000069442A1/en not_active Ceased
- 2000-05-11 TR TR2002/00260T patent/TR200200260T2/xx unknown
- 2000-05-11 AU AU48364/00A patent/AU776000B2/en not_active Expired
- 2000-05-11 NZ NZ515626A patent/NZ515626A/en not_active IP Right Cessation
- 2000-05-11 EP EP00930565A patent/EP1183030A4/en not_active Withdrawn
-
2001
- 2001-06-11 US US09/877,103 patent/US6506753B2/en not_active Expired - Lifetime
- 2001-11-13 NO NO20015542A patent/NO321674B1/no not_active IP Right Cessation
-
2002
- 2002-01-09 US US10/040,475 patent/US6458791B1/en not_active Expired - Lifetime
- 2002-09-30 US US10/259,851 patent/US20030119841A1/en not_active Abandoned
-
2003
- 2003-01-13 US US10/340,957 patent/US6946464B2/en not_active Expired - Fee Related
-
2005
- 2005-09-20 US US11/229,699 patent/US20060025418A1/en not_active Abandoned
-
2006
- 2006-05-09 NO NO20062092A patent/NO20062092L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU776000B2 (en) | 2004-08-19 |
| TR200200260T2 (tr) | 2002-05-21 |
| NO20062092L (no) | 2002-01-14 |
| EP1183030A4 (en) | 2007-11-21 |
| CA2373797C (en) | 2010-07-27 |
| NO20015542L (no) | 2002-01-14 |
| US20030166657A1 (en) | 2003-09-04 |
| US6339086B1 (en) | 2002-01-15 |
| AU4836400A (en) | 2000-12-05 |
| NO20015542D0 (no) | 2001-11-13 |
| EP1183030A1 (en) | 2002-03-06 |
| US6506753B2 (en) | 2003-01-14 |
| NO321674B1 (no) | 2006-06-19 |
| US20060025418A1 (en) | 2006-02-02 |
| US6458791B1 (en) | 2002-10-01 |
| WO2000069442A1 (en) | 2000-11-23 |
| JP2002544232A (ja) | 2002-12-24 |
| KR20020008405A (ko) | 2002-01-30 |
| NZ515626A (en) | 2004-04-30 |
| MXPA01011534A (es) | 2002-06-04 |
| US20030119841A1 (en) | 2003-06-26 |
| US6946464B2 (en) | 2005-09-20 |
| US20020143016A1 (en) | 2002-10-03 |
| CA2373797A1 (en) | 2000-11-23 |
| US20020019398A1 (en) | 2002-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1832734B (zh) | 用于治疗抑郁症的取代的2-氨基1,2,3,4-四氢化萘 | |
| US8754119B2 (en) | Use of rotigotine for the treatment of depression | |
| RU2473343C2 (ru) | Лечение туберозного склероза | |
| BR0012136A (pt) | Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos | |
| EA200400881A1 (ru) | Азаарилпиперазины | |
| BR0011823A (pt) | Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo | |
| CA2373797A1 (en) | Methods of treating or preventing affective disorders | |
| DK1106178T3 (da) | Anvendelse af ibudilast til fremstilling af et lægemiddel til behandling af dissemineret sklerose | |
| Sebban et al. | Effects of phencyclidine (PCP) and MK 801 on the EEGq in the prefrontal cortex of conscious rats; antagonism by clozapine, and antagonists of AMPA‐, α1‐and 5‐HT2A‐receptors | |
| JP2012197304A (ja) | ミオパシー関連性の覚醒障害を矯正することが意図される医薬品を製造するためのモダフィニルの使用 | |
| Vecchierini | Sleep disturbances in Alzheimer’s disease and other dementias | |
| TWI250872B (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
| MEP2508A (xx) | Tretiranje neurotskih poremećaja | |
| RU2292881C2 (ru) | Соединения карбамата для применения при профилактике или лечении тревожных расстройств | |
| Lin et al. | Silent information regulator sirtuin 1-mediated neuronal excitation-inhibition imbalance in the central amygdala is involved in peripheral nerve injury-induced depression-related behavior in mice | |
| AU2004266494B2 (en) | Alpha-aminoamide derivatives useful as anti-inflammatory agents | |
| KR100407399B1 (ko) | 세로토닌 ｎ-아세틸트란스퍼라제의 활성 억제제 | |
| Franco-Pérez et al. | Quinine, a selective gap junction blocker, decreases REM sleep in rats | |
| CA2494660A1 (en) | Use of carboxamides for the treatment of tinnitus | |
| Lader | Antianxiety drugs: clinical pharmacology and therapeutic use | |
| DK0839137T3 (da) | Aromatiske carboxylsyrediamider med antigastrinvirkning, fremgangsmåde til deres fremstilling samt deres anvendelse som lægemidler | |
| EP1632235A3 (en) | Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders | |
| BR112020011401A2 (pt) | combinação de moduladores de receptor nmda (rapastinel) para uso em tratamento combinado (distúrbio do sono e do snc) | |
| WO2018095264A1 (zh) | Notch信号通路调控剂调节骨生成 | |
| Baxendale et al. | Clinical implications of circadian rhythmicity for nurses and patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: ATRAVES DA PETICAO NO 025108, DE 12/05/2003, O REQUERENTE SOLICITOU O EXAME DO PRESENTE PEDIDO E EFETUOU A RETRIBUICAO EQUIVALENTE A 14 REIVINDICACOES. NO ENTANTO, PELA PETICAO NO 039380, DE 31/07/2003 FOI APRESENTADO UM NOVO QUADRO REIVINDICATORIO CONSTANDO 34 REVINDICACOES. DESSE MODO, A FIM DE DAR CONTINUIDADE AO EXAME DO PEDIDO O REQUERENTE DEVERA COMPLEMENTAR A RETRIBUICAO REFERENTE AS 20 REIVINDICACOES QUE EXCEDEM AS 14 APRESENTADAS. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A,9A E 10A ANUIDADES |
|
| B08J | Incorrect entry in the gazette republished [chapter 8.10 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2073 DE 28/09/2010. TEXTO CORRETO: REFERENTE A 9A, 10A E 11A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2095 DE 01/03/2011. |